信邦制药(002390) - 2024 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2024 was ¥6,032,262,052.57, a decrease of 6.63% compared to ¥6,460,841,315.46 in 2023[23]. - The net profit attributable to shareholders for 2024 was ¥101,381,622.75, down 64.70% from ¥287,232,798.94 in 2023[23]. - The net profit after deducting non-recurring gains and losses was ¥165,318,585.59, a decrease of 38.29% from ¥267,902,516.17 in 2023[23]. - The net cash flow from operating activities for 2024 was ¥634,968,962.59, down 19.69% from ¥790,618,030.35 in 2023[23]. - Basic earnings per share for 2024 were ¥0.05, a decline of 66.67% compared to ¥0.15 in 2023[23]. - Total assets at the end of 2024 were ¥9,028,336,478.89, a decrease of 2.34% from ¥9,244,971,150.19 at the end of 2023[23]. - The net assets attributable to shareholders at the end of 2024 were ¥6,710,056,421.59, down 2.08% from ¥6,852,401,324.17 at the end of 2023[23]. - The company reported a significant decline in quarterly net profit in Q4 2024, with a loss of ¥75,207,952.15 compared to profits in the previous quarters[27]. - In 2024, the company achieved operating revenue of CNY 603.23 million, a year-on-year decrease of 6.63%, and net profit attributable to shareholders was CNY 101.38 million, down 64.70%[75]. - The total operating revenue for the company was CNY 6,032.26 million in 2024, a decrease of 6.63% compared to CNY 6,460.84 million in 2023[84]. Dividend Distribution - The company plans to distribute a cash dividend of 0.30 RMB per 10 shares to all shareholders, based on a total share capital of 1,896,406,328 shares after deducting repurchased shares[4]. - The company plans to distribute a cash dividend of 0.60 CNY per 10 shares for the 2023 fiscal year, totaling approximately 114.4 million CNY[170]. - For the first half of 2024, the company will distribute a cash dividend of 0.30 CNY per 10 shares, amounting to around 56.9 million CNY[172]. - The total number of shares eligible for the 2023 dividend distribution is 1,906,619,328 shares after accounting for repurchased shares[170]. - The total number of shares eligible for the 2024 semi-annual dividend distribution is 1,896,406,328 shares after accounting for repurchased shares[172]. - The company's profit available for distribution to shareholders is approximately 456.8 million CNY[172]. - The cash dividend distribution for 2024 represents 100% of the profit distribution total[172]. Market Position and Strategy - The company is positioned in a robust healthcare market driven by increasing healthcare expenditure and an aging population in China[33]. - The healthcare expenditure in China for 2023 reached ¥90,575.8 billion, accounting for 7.20% of GDP, indicating a growing market demand[34]. - The company is focusing on quality control in its traditional Chinese medicine pieces to ensure product stability and safety, which is expected to drive growth in this segment[63]. - The company is committed to integrating traditional Chinese medicine with modern healthcare practices, enhancing its service offerings and competitive positioning[64]. - The company is exploring deep integration of online and offline services to provide more efficient and high-quality services to customers[49]. - The company aims to enhance its channel capabilities and service radius by optimizing its distribution network between urban and rural areas[48]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and diversify its product offerings[139]. Research and Development - The company is working on a major R&D project to optimize the preparation process of a traditional Chinese herb, aiming to enhance product quality and establish operational standards[97]. - The R&D project is expected to contribute to the company's growth by developing high-value-added products and improving market competitiveness[97]. - The company has allocated significant resources towards research and development, with a budget of 602.83 million for the current year[139]. - The company has implemented comprehensive training on pharmaceutical and medical device regulations to improve quality management capabilities[167]. - The company has published 261 articles, including 40 in SCI journals, and received 23 research project approvals, including 3 national-level projects[77]. Governance and Compliance - The company adheres to legal regulations and has improved its corporate governance structure, ensuring compliance with the requirements set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[129]. - The company has established a market value management system and disclosed its valuation enhancement plan[127]. - The company has a complete and independent financial management system, ensuring it operates without shared bank accounts with its controlling shareholder[133]. - The company has established an internal audit system to effectively control daily operations and significant related transactions[131]. - The company is committed to strict compliance with the Company Law and regulatory rules set by the China Securities Regulatory Commission[158]. - The company has a structured process for board meetings, ensuring transparency and accountability in decision-making[153]. Environmental Responsibility - The company adheres to strict environmental standards for wastewater and emissions, complying with relevant regulations[182]. - The company holds valid pollution discharge permits for its facilities, with expiration dates ranging from 2026 to 2028[183]. - The company has implemented a long-term mechanism for energy conservation and emission reduction, focusing on the recycling of cooling water and steam condensate[197]. - The company plans to invest 1.36 million in environmental governance and protection for the year 2024[194]. - The company has established a dynamic environmental monitoring system in compliance with national and local regulations[197]. Employee Development - The total number of employees at the end of the reporting period was 5,059, with 285 in the parent company and 4,774 in major subsidiaries[163]. - The company conducted 1,046 training sessions in 2024, covering 20,483 employee instances, with a total expenditure of 1.2509 million yuan[165]. - The company has established a multi-dimensional training system to support employee growth and strategic development[169]. - The company emphasizes a salary policy that aligns responsibility with benefits, aiming for a fair and efficient compensation system[164]. - The company has 3,003 technical personnel, representing approximately 59.3% of the total workforce[163].